Page 28 - Acute Pancreatitis (Viêm tụy cấp)

References 916.e3

110. Haber CJ, Meltzer SJ, Present DH, et al. Nature and course of pan- 137. Elmunzer JB. Reducing the risk of post-endoscopic retrograde chol-
creatitis caused by 6 mercaptopurine in the treatment of inflamma- angiopancreatography pancreatitis. Dig Endosc 2017;29:749–57. 58
tory bowel disease. Gastroenterology 1986;91:982–6. 138. Mehta SN, Pavone E, Barkun JS, et al. Predictors of post-ERCP
111. Lederle FA, Bloomfield HE. Drug treatment of asymptomatic hy- complications in patients with suspected choledocholithiasis. En-
pertriglyceridemia to prevent pancreatitis. Where is the evidence? doscopy 1998;30:457–63.
Ann Intern Med 2012;157:662–4. 139. Katsinelos P, Lazaraki G, Chatzimavroudis G, et al. Risk factors for
112. Glueck CJ, Lang J, Hamer T, et al. Severe hypertriglyceridemia and therapeutic ERCP-related complications: an analysis of 2,715 cases
pancreatitis when estrogen replacement therapy is given to hypertri- performed by a single endoscopist. Ann For 2014;27:65–72.
glyceridemic women. J Lab Clin Med 1994;123:59–64. 140. Testoni PA, Bagnolo F, Caporuscio S, et al. Serum amylase mea-
113. Whitfield JB, Hensley WJ, Bryden D, et al. Some laboratory cor- sured four hours after endoscopic sphincterotomy is a realiable
relates of drinking habit. Ann Clin Biochem 1978;15:294–303. predictor of post-procedure pancreatitis. Am J Gastroenterology
114. Carr RA, Rejowski BJ, Cote GA, et al. Systematic review of hyper- 1999;94:1235–52.
triglyceridemia-induced acute pancreatitis: a more virulent etiol- 141. Gottlieb K, Sherman S, Pezzi J, et al. Early recognition of post-
ogy? Pancreatology 2016;16:469–76. ERCP pancreatitis by clinical assessment and serum pancreatic en-
115. Wang Q, Wang G, Qiu Z, et al. Elevated serum triglycerides in zymes. Am J Gastroenterol 1996;91:1553–61.
the prognostic assessment of acute pancreatitis: a systematic review 142. Murray B, Carter R, Imrie C, et al. Diclofenac reduces the incidence
and meta-analysis of observational studies. J Clin Gastroenterol of acute pancreatitis after endoscopic retrograde cholangiopancrea-
2017;51:586–93. tography. Gastroenterology 2003;124:1786–91.
116. Steinberg WM, Nauck MA, Zinman B, et al. LEADER 3-lipase and 143. Ito K, Fujita J, Noda Y, et al. Relationship between post-ERCP pan-
amylase activity in subjects with type 2 diabetes: baseline data from creatitis and the change of serum amylase level after the procedure.
over 9000 subjects in the LEADER trial. Pancreas 2014;43:1223– World J Gastroenterol 2007;13:3855–60.
31. 144. Manes G, Ardizzone S, Lombardi G, et al. Efficacy of postproce-
117. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 dia- dure administration of gabexate mesylate in the prevention of post-
betes treated with exenatide or sitagliptin: a retrospective observa- ERCP pancreatitis: a randomized, controlled, multicenter study.
tional pharmacy claims analysis. Diabetes Care 2010;33:2349–54. Gastrointest Endosc 2007;65:982–7.
118. Girman C, Kou P, Cai B, et al. Patients with type 2 diabetes mellitus 145. Elmunzer JB, Serrano J, Chak A, et al. Rectal indomethacin alone
have higher risk for acute pancreatitis compared with those without versus indomethacin and prophylactic pancreatic stent placement
diabetes. Diabetes Obes Metab 2010;12:766–71. for preventing pancreatitis after ERCP: study protocol for a ran-
119. Noel RA, Patterson RE, Braun DK, et al. Increased risk of acute domized controlled trial. Trials 2016;17:120.
pancreatitis and biliary disease observed in patients with type 2 dia- 146. Olsson G, Lubbe J, Arnelo U, et al. The impact of prophylactic pan-
betes. Diabetes Care 2009;32:834–8. creatic stenting on post-ERCP pancreatitis: a nationwide, register-
120. Mithofer K, Fernandez-del Castillo C, Frick TW. Acute hypercal- based study. United European Gastroenterol J 2017;5:111–8.
cemia causes acute pancreatitis and ectopic trypsinogen activation in 147. Kerdsirichairat T, Attam R, Arain M, et al. Urgent ERCP with pan-
the rat. Gastroenterology 1995;109:239–46. creatic stent placement or replacement for salvage of post-ERCP
121. Prinz RA, Aranha GV. The association of primary hyperparathy- pancreatitis. Endoscopy 2014;46:1085–94.
roidism and pancreatitis. Am Surg 1985;51:325–9. 148. Tse F, Yuan Y, Moayyedi P, et al. Double-guidewire technique
122. Khoo TK, Vege SS, Abu-Lebdeh HS, et al. Acute pancreatitis in in difficult biliary cannulation for the prevention of post-ERCP
primary hyperparathyroidism: a population-based study. J Clin En- pancreatitis: a systematic review and meta-analysis. Endoscopy
docrinol Metab 2009;94:2115–8. 2017;49:15–26.
123. Takasaki M, Yorimitsu Y, Takahashi I, et al. Systemic lupus ery- 149. Elmunzer BJ, Scheiman JM, Lehman GA, et al. A randomized trial
thematosus presenting with drug-unrelated acute pancreatitis as an of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J
initial manifestation. Am J Gastroenterol 1995;90:1172–3. Med 2012;366:1414–22.
124. Watts RA, Isenberg DA. Pancreatic disease in the autoimmune 150. Wan J, Ren Y, Zhu Z, et al. How to select patients and timing for
rheumatic disorders. Semin Arthritis Rheum 1989;19:158–65. rectal indomethacin to prevent post-ERCP pancreatitis: a system-
125. Orvar K, Johlin FC. Atheromatous embolization resulting in acute atic review and meta-analysis. BMC Gastroenterol 2017;17:43.
pancreatitis after cardiac catheterization and angiographic studies. 151. Luo H, Zhao L, Leung J, et al. Routine pre-procedural rectal in-
Arch Intern Med 1994;154:1755. dometacin versus selective post-procedure rectal indometacin to
126. Fernandez-del Castillo C, Harringer W, Warshaw AL, et al. Risk prevent pancreatitis in patients undergoing endoscopic retrograde
factors for pancreatic cellular injury after cardiopulmonary bypass. cholangiopancreatography: a multicentre, single-blinded, random-
N Engl J Med 1991;325:382–7. ized controlled trial. Lancet 2016;387:2293–301.
127. Warshaw AL, O Hara PJ. Susceptibility of the pancreas to ischemic 152. He X, Zheng W, Ding Y, et al. Rectal indomethacin is protective
injury in shock. Ann Surg 1978;188:197–201. against pancreatitis after endoscopic retrograde cholangiopancrea-
128. Reilly PM, Toung TJ, Miyachi M, et al. Hemodynamics of pan- tography: systematic review and meta-analysis. Gastroenterol Res
creatic ischemia in cardiogenic shock in pigs. Gastroenterology Pract 2018;2018:9784841.
1997;113:938–45. 153. Yu LM, Zhao KJ, Lu B. Use of NSAIDs via the rectal route for the
129. Ertan A, Schneider FE. Acute pancreatitis in long-distance runners. prevention of pancreatitis after ERCP in all-risk patients: an up-
Am J Gastroenterol 1995;90:70–1. dated meta-analysis. Gastroenterol Res Pract 2018;2018:1027530.
130. Wilson RH, Moorehead RJ. Current management of trauma to the 154. Smeets XJ, da Costa DW, Besselink MG, et al. Systematic review:
pancreas. Br J Surg 1991;78:1196–202. periprocedural hydration in the prevention of post-ERCP pancre-
131. Kozarek RA, Ball TJ, Patterson DJ, et al. Endoscopic transpapillary atitis. Aliment Pharmacol Ther 2016;44:541–53.
therapy for disrupted pancreatic duct and peripancreatic fluid col- 155. Wu D, Wan J, Xia L, et al. The efficiency of aggressive hydration
lections. Gastroenterology 1991;100:1362–70. with lactated ringer solution for the prevention of post-ERCP pan-
132. Nwariaku FE, Terracina A, Mileski WJ, et al. Is octreotide benefi- creatitis: a systematic review and meta-analysis. J Clin Gastroenterol
cial following pancreatic injury? Am J Surg 1995;170:582–5. 2017;51:e68–76.
133. Aliperti G. Complications related to diagnostic and therapeutic 156. Smeets X, da Costa DW, Fockens P, et al. Fluid hydration to pre-
endoscopic retrograde cholangiopancreatography. Gastrointest En- vent post-ERCP pancreatitis in average-to high-risk patients receiv-
dosc Clin North Am 1996;6:379–407. ing prophylactic rectal NSAIDs (FLUYT trial): study protocol for a
134. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post- randomized controlled trial. Trials 2018;19:207.
ERCP pancreatitis: a prospective, multicenter study. Gastrointest 157. Bragg Le, Thompson JS, Burnett DA, et al. Increased incidence of
Endosc 2001;54:425–34. pancreas-related complications in patients with postoperative pan-
135. Kochar B, Akshintala VS, Afghani E, et al. Incidence, severity, and creatitis. Am J Surg 1985;150:694–7.
mortality of post-ERCP pancreatitis: a systematic review by using 158. Lefor AT, Vuocolo P, Parker FB, et al. Pancreatic complications
randomized, controlled trials. Gastrointest Endosc 2015;81:143–9 e9. following cardiopulmonary bypass: factors influencing mortality.
136. Cheng CL. Risk factors for post ERCP pancreatitis: a prospective Arch Surg 1992;127:1225–30.
multicenter study. Am J Gastroenterol 2006;101:139–47. 159. Camargo CA, Greig PD, Levy GA, et al. Acute pancreatitis follow-
ing liver transplantation. J Am Coll Surg 1995;181:249–56.